Ligand Pharmaceuticals - Biopharma's Technology and Capital …
Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the …
Ligand Pharmaceuticals Incorporated - Investor Relations
2024年11月7日 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of …
About Us - Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs …
Royalty Portfolio - Ligand Pharmaceuticals
Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 100 partnered commercial and development stage …
Team - Ligand Pharmaceuticals
Before joining Ligand, Dr. Reeves served as President and Chief Medical Officer of AZTherapies, Inc., a private, late-stage clinical biopharmaceutical company focused on developing drugs for …
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol ...
2019年5月2日 · The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand …
Ligand Announces Launch of Pelthos Therapeutics to Accelerate ...
2024年4月3日 · Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of …
Ligand Reports Third Quarter 2024 Financial Results and Raises …
Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. …
News & Events - Press Releases - Ligand Pharmaceuticals
2024年7月8日 · At Ligand Pharmaceuticals Incorporated, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE ...
2024年6月18日 · Ligand will now collect commercial royalties on six products developed with the Pfenex Expression Technology, including Merck’s CAPVAXIVE and VAXNEUVANCE ®, Jazz …
- 某些结果已被删除